# Ipamorelin Benefits Reported in Research: The Bone and Body-Composition Data > Ipamorelin benefits reported in research: dose-graded bone growth (42 to 52 microm/day), higher bone mineral content, steroid-bone rescue, and a clean cortisol-sparing GH pulse. Cited. The skeletal and body-composition findings, gathered in one place, with every figure tied to the study that measured it. ## The gist The ipamorelin benefits reported in research are mostly skeletal and mostly from rats. The headline is a dose-response: more ipamorelin meant faster bone growth, in steady steps. Over longer exposure, bones in rats carried more total mineral and grew larger. When a steroid was working against bone, ipamorelin partly pushed back. And underneath all of it sits the molecule's signature trick — it raises growth hormone without raising the stress hormone cortisol, which is what separates it from older peptides in its family. These are animal findings measured carefully, plus a small amount of human pharmacology; none of it is a proven human benefit, and the community-reported upsides like better sleep live separately on the effects page because they are anecdotal. ## Dose-graded bone growth: the cleanest benefit on record The most quantitatively satisfying ipamorelin benefit is a stepwise bone-growth response. Subcutaneous ipamorelin at 18, 90 and 450 microg/day (split three times daily for 15 days) lifted longitudinal bone growth rate in adult female rats from 42 microm/day on vehicle to 44, 50 and 52 microm/day — each dose a clear step up [2]. The accompanying detail matters: total IGF-1 (the liver's growth-relay hormone) and bone-turnover markers did not measurably move, so the skeletal gain tracked the dose without a matching rise in circulating growth factor — a partly local, pulse-driven effect [2]. It is preclinical and short (15 days), but it is the dose-response that anchors this site's bone-skeletal reading. ## More bone mineral, bigger bones Longer exposure builds on that. Continuous ipamorelin 0.5 mg/kg/day by osmotic minipump for 12 weeks raised total tibial and vertebral bone mineral content on DXA in young female rats, while cortical volumetric bone mineral density was unchanged [3]. The honest interpretation is dimensional: the bones got bigger and held more total mineral, but the cortex did not get denser — growth by expansion rather than densification [3]. It is a real, measured skeletal benefit, and it is also a precise one — worth stating exactly, because "bigger bones" and "denser bones" are not the same claim. ## Holding bone against a steroid Glucocorticoids erode bone formation, and ipamorelin partly counters that. In 8-month-old female rats, ipamorelin 100 microg/kg three times daily for 3 months (alongside methylprednisolone) raised the periosteal bone formation rate roughly four-fold versus the steroid alone and increased maximum tetanic muscle tension [4]. A companion study confirmed the growth-hormone response to ipamorelin was not blunted by methylprednisolone, and that the combination raised IGF-1 and improved body-weight recovery versus steroid alone [5]. The benefit here is resilience — ipamorelin's pulse keeps working under a glucocorticoid load that would otherwise suppress bone formation. ## The benefit that underlies all the others: selectivity The mechanistic benefit threading through every result is clean selectivity. Ipamorelin releases growth hormone potently — swine ED50 `2.3 nmol/kg`, comparable to GHRP-6 — but does not raise ACTH or cortisol above the GHRH-induced level even at doses more than 200-fold above its growth-hormone ED50 [1]. That means the skeletal and body-composition effects come without the adrenal stimulation and prolactin rise that older growth-hormone-releasing peptides carry [1]. It is the reason ipamorelin is described as the first selective growth-hormone secretagogue, and the reason its benefit profile reads cleaner than its predecessors'. ## The muscle and recovery signal — preclinical, not proven A second cluster of reported ipamorelin benefits centers on muscle and recovery, and here the evidence is thinner and animal-bound. In the steroid-rescue rat study, ipamorelin did not just protect bone — it raised maximum tetanic muscle tension, the peak force a muscle can generate, versus the steroid alone [4]. A 2026 orthopaedic review extended this to the combination: CJC-1295 plus ipamorelin improved maximum tetanic tension in a glucocorticoid-induced muscle-loss model in mice, though the authors stressed the evidence is limited to animal studies [16]. There is no controlled human trial showing ipamorelin builds muscle, so this sits as a preclinical signal — real in rodents, unproven in people. It is worth keeping separate from the community-reported recovery accounts, which are anecdotal rather than measured. ## The metabolic and body-composition picture Beyond bone and muscle, ipamorelin's reported benefits brush against metabolism and body composition — and the data here is mixed enough to demand care. In mice, ipamorelin stimulated adiposity and raised leptin independently of growth hormone after two weeks of dosing [11], meaning part of its body-composition effect runs through direct ghrelin-receptor signaling rather than the growth-hormone axis. In a 2024 ferret model, ipamorelin (1-3 mg/kg) blunted chemotherapy-induced body-weight loss by about 24% — a peripheral anti-cachexia effect, useful context for the weight-preservation angle, but not the same as fat loss [8]. The community framing of ipamorelin as a lean-out compound therefore outruns the controlled evidence: the measured signals point to weight preservation and growth-hormone-independent fat-tissue effects in animals, not a demonstrated human fat-loss benefit. ## Where the benefits stop, stated plainly An honest benefits page has to mark its own edges. Every skeletal and muscle finding above is preclinical — rats and mice, not human outcomes — and the only human efficacy test ipamorelin ever faced, a Phase 2 trial for slowed bowel recovery after surgery, missed its primary endpoint [7]. The human pharmacology that does exist is limited to one small dose-ranging study [6]. So the benefits reported in research are best read as a strong, reproducible animal signal — particularly on the skeletal side — paired with an honest absence of proven human benefit. For the community-reported, non-clinical upsides — sleep, recovery, body composition over time — see the [Ipamorelin effects](/effects) page, where they are clearly labeled anecdotal, not clinical evidence. --- A data-forward read of the ipamorelin record — the rat bone-growth numbers and the cortisol-sparing GH pulse logged first, each figure pinned to the study that measured it and the thin, mostly-negative human evidence left plainly thin; a reading console, not a clinic, a vendor, or a prescription.